Description
Product details
THEO-SLO LEVO LD Levosalbutamol Respiratory Solution 0.31 mg delivers targeted bronchodilation through nebulization, making it an essential therapy for asthma, COPD, and acute bronchospasm in adults and children. This low-dose formulation of the active R-isomer of salbutamol relaxes airway muscles swiftly, improving airflow and reducing symptoms like wheezing and shortness of breath. Ideal for patients needing gentle yet effective respiratory support, it ensures deep lung delivery via fine mist for optimal efficacy. Key Uses of THEO-SLO LEVO LD Levosalbutamol Respiratory Solution 0.31 mg THEO-SLO LEVO LD addresses obstructive airway diseases by directly targeting bronchial constriction. Primary indications include acute asthma attacks, chronic bronchitis, emphysema, and exercise-induced symptoms, where it restores normal breathing patterns efficiently. Asthma Management: Relieves wheezing, chest tightness, and breathlessness during flare-ups or as maintenance therapy. COPD Support: Eases airflow restriction in chronic bronchitis and emphysema, enhancing daily activities. Acute Bronchospasm: Provides fast intervention for triggers like allergens, infections, or pollutants. Exercise-Induced Relief: Prevents airway narrowing during physical exertion. Pediatric and Elderly Use: Nebulizer-friendly for young children or those unable to use inhalers. Administered via nebulizer, dilute as prescribed (typically 0.31 mg in 2-3 ml saline) for 5-10 minute sessions, 2-4 times daily based on severity. Key Benefits of THEO-SLO LEVO LD Levosalbutamol Respiratory Solution 0.31 mg As the purified R-isomer, Levosalbutamol in THEO-SLO LEVO LD offers higher potency and fewer side effects than racemic salbutamol, with rapid onset within minutes. Its nebulized form penetrates deeper into lungs, making it superior for severe cases or coordination-challenged patients. Quick Bronchodilation: Relaxes smooth muscles to open airways, improving oxygen intake immediately. Enhanced Tolerability: Lower cardiac stimulation reduces tachycardia risk compared to standard albuterol. Patient-Friendly Delivery: Mist form suits infants, seniors, and acute distress without coordination needs. Symptom Control: Decreases cough frequency, wheezing intensity, and respiratory distress for better quality of life. Longer Relief Duration: Sustained action supports maintenance therapy alongside controllers like steroids. Clinical use shows improved lung function (FEV1 increase by 20-30%) and reduced hospitalization rates in responsive patients. Potential Side Effects and Precautions for THEO-SLO LEVO LD THEO-SLO LEVO LD remains well-tolerated at 0.31 mg, with most effects mild and transient. Monitor during initial use, especially in cardiac patients. Common Mild Effects: Tremors, nervousness, headache, or mild palpitations resolving quickly. Less Frequent: Dry mouth, throat irritation, or muscle cramps from overuse. Rare Serious: Hypokalemia, paradoxical bronchospasm, or severe tachycardia—seek immediate care. Avoid in hypersensitivity, uncontrolled arrhythmias, or with beta-blockers. Use cautiously in pregnancy (Category C), hyperthyroidism, diabetes, or hypertension; taper during weaning. Dosage Guidelines and Best Practices For adults/children >12 years: 0.31-0.63 mg nebulized 3-4 times daily; children 2-12 years: half dose. Always dilute, use fresh solution, and clean nebulizer post-use. Combine with anti-inflammatories for chronic management; do not exceed recommended frequency. Conclusion: Breathe Easier with THEO-SLO LEVO LD Levosalbutamol Respiratory Solution 0.31 mg THEO-SLO LEVO LD Levosalbutamol Respiratory Solution 0.31 mg transforms respiratory care by offering swift, reliable bronchodilation for asthma, COPD, and bronchospasm across age groups. Its selective action, nebulizer compatibility, and safety profile make it a cornerstone for symptom relief and lung health preservation. Consult healthcare providers for integrated therapy to achieve optimal breathing freedom and prevent exacerbations.







